HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raised the price target from $36 to $48.
May 20, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Dyne Therapeutics and raised the price target from $36 to $48, indicating strong confidence in the company's future performance.
The raised price target from $36 to $48 by HC Wainwright & Co. suggests a positive outlook for Dyne Therapeutics, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100